Biogen Inc. · NASDAQ:BIIB
Biogen — Merger or Acquisition (July 2023)
8 slides from Biogen's merger presentation, Jul 28, 2023
Slide 1: Proposed Acquisition of Reata Pharmaceuticals, Inc. Investor Webcast
Exhibit 99.2 Proposed Acquisition of Reata Pharmaceuticals, Inc. Investor Webcast July 28, 2023
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and da
Slide 3: Agenda
Agenda Chuck Triano Introduction Head of Investor Relations Christopher A. Viehbacher Strategic Overview President and Chief Executive Officer Michael McDonnell Financial Highlights Chief Financial Officer Adam Keeney Available for Q&A Head of Corporate Development 3
Slide 4: Reata acquisition expected to meaningfully advance Biogen's return to growth objective
Reata acquisition expected to meaningfully advance Biogen’s return to growth objective • Acquisition expected to help drive revenue growth and Non-GAAP EPS growth ® • Lead program SKYCLARYS (omaveloxone) is a first-in-class Nrf2 activator recently De-risked approved by FDA (Feb’23) as the only treat
Slide 5: Friedreich's ataxia is a devastating, rare, genetic, neuromuscular disease
Friedreich’s ataxia is a devasting, rare, genetic, neuromuscular disease affecting the nervous system and heart • Rare, genetic disorder with slow progression in which neurodegeneration leads to multi-system impact and Problems with speech and swallowing functional declines Spasticity • Caused by a
Slide 6: SKYCLARYS is the first and only approved treatment in Friedreich's ataxia
SKYCLARYS is the first and only approved treatment in Friedreich’s ataxia with potential to become the standard of care • SKYCLARYS is the first therapy approved in FA in the US, offering a clinically meaningful advancement in treating a debilitating disease • Clear and clinically meaningful benefit
Slide 7: Financial overview
Financial overview • Biogen has agreed to acquire all outstanding shares of Reata for $172.50 per share, representing an enterprise value of ~$7.3 billion Transaction • No financing conditions. Expect to finance the acquisition with cash on hand, Details supplemented by the issuance of term debt •
Slide 8: Questions & Answers
Questions & Answers 8 8